Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dust mite mixture for pediatric allergic asthma
CTR20131571Phase 2Completed
- Sponsor
- Wolwo Biotech
- Start
- Nov 2016
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of house dust mite allergen sublingual immunotherapy in allergic asthma, sponsored by Wolwo Biotech. Started Nov 2016; status: completed.
02
Drugs
house dust mite allergen sublingual immunotherapy
03
Conditions
allergic asthma
Beyond the preview
Go deeper on CTR20131571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131571.